Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Gareth R Evans

Showing results (81-90 of 102) with videos related to

Pageof 11
Sort By:
Genetics in Medicine : Official Journal of the American College of Medical Genetics|August 3, 2024
Extended panel testing in ovarian cancer reveals BRIP1 as the third most important predisposition geneRobert D Morgan, George J Burghel, Nicola Flaum, et al.
International Journal of Epidemiology|January 9, 2022
Prospective evaluation of a breast-cancer risk model integrating classical risk factors and polygenic risk in 15 cohorts from six countriesAmber N Hurson, Parichoy Pal Choudhury, Chi Gao, et al.
Nature Communications|March 27, 2025
Spatial mapping of immune cell environments in NF2-related schwannomatosis vestibular schwannomaAdam P Jones, Michael J Haley, Miriam H Meadows, et al.
The New England Journal of Medicine|May 28, 2015
Gene-panel sequencing and the prediction of breast-cancer riskDouglas F Easton, Paul D P Pharoah, Antonis C Antoniou, et al.
Human Mutation|November 16, 2005
Identification of genetic aberrations on chromosome 22 outside the NF2 locus in schwannomatosis and neurofibromatosis type 2Patrick G Buckley, Kiran K Mantripragada, Teresita Díaz de Ståhl, et al.
Journal of Clinical Pathology|June 23, 2022
Predicting the likelihood of a <i>BRCA1/2</i> pathogenic variant being somatic by testing only tumour DNA in non-mucinous high-grade epithelial ovarian cancerRobert D Morgan, George J Burghel, Nicola Flaum, et al.
Breast Cancer Research : BCR|December 3, 2015
Mammographic density adds accuracy to both the Tyrer-Cuzick and Gail breast cancer risk models in a prospective UK screening cohortAdam R Brentnall, Elaine F Harkness, Susan M Astley, et al.
British Journal of Cancer|November 16, 2024
Germline BRCA1/2 status and chemotherapy response score in high-grade serous ovarian cancerRobert D Morgan, Xin Wang, Bethany M Barnes, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 5, 2017
Cancer Screening Recommendations and Clinical Management of Inherited Gastrointestinal Cancer Syndromes in ChildhoodMaria Isabel Achatz, Christopher C Porter, Laurence Brugières, et al.
European Journal of Human Genetics : EJHG|July 12, 2020
Mainstreaming germline BRCA1/2 testing in non-mucinous epithelial ovarian cancer in the North West of EnglandNicola Flaum, Robert D Morgan, George J Burghel, et al.
Pageof 11

Showing results (81-90 of 102) with videos related to

Sort By:
Pageof 11
Genetics in Medicine : Official Journal of the American College of Medical Genetics|August 3, 2024
Extended panel testing in ovarian cancer reveals BRIP1 as the third most important predisposition geneRobert D Morgan, George J Burghel, Nicola Flaum, et al.
International Journal of Epidemiology|January 9, 2022
Prospective evaluation of a breast-cancer risk model integrating classical risk factors and polygenic risk in 15 cohorts from six countriesAmber N Hurson, Parichoy Pal Choudhury, Chi Gao, et al.
Nature Communications|March 27, 2025
Spatial mapping of immune cell environments in NF2-related schwannomatosis vestibular schwannomaAdam P Jones, Michael J Haley, Miriam H Meadows, et al.
The New England Journal of Medicine|May 28, 2015
Gene-panel sequencing and the prediction of breast-cancer riskDouglas F Easton, Paul D P Pharoah, Antonis C Antoniou, et al.
Human Mutation|November 16, 2005
Identification of genetic aberrations on chromosome 22 outside the NF2 locus in schwannomatosis and neurofibromatosis type 2Patrick G Buckley, Kiran K Mantripragada, Teresita Díaz de Ståhl, et al.
Journal of Clinical Pathology|June 23, 2022
Predicting the likelihood of a <i>BRCA1/2</i> pathogenic variant being somatic by testing only tumour DNA in non-mucinous high-grade epithelial ovarian cancerRobert D Morgan, George J Burghel, Nicola Flaum, et al.
Breast Cancer Research : BCR|December 3, 2015
Mammographic density adds accuracy to both the Tyrer-Cuzick and Gail breast cancer risk models in a prospective UK screening cohortAdam R Brentnall, Elaine F Harkness, Susan M Astley, et al.
British Journal of Cancer|November 16, 2024
Germline BRCA1/2 status and chemotherapy response score in high-grade serous ovarian cancerRobert D Morgan, Xin Wang, Bethany M Barnes, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 5, 2017
Cancer Screening Recommendations and Clinical Management of Inherited Gastrointestinal Cancer Syndromes in ChildhoodMaria Isabel Achatz, Christopher C Porter, Laurence Brugières, et al.
European Journal of Human Genetics : EJHG|July 12, 2020
Mainstreaming germline BRCA1/2 testing in non-mucinous epithelial ovarian cancer in the North West of EnglandNicola Flaum, Robert D Morgan, George J Burghel, et al.
Pageof 11